The biotech arm of one of the largest global real estate investors was able to capitalize on soaring demand for Bay Area research and development space with a deal to offload two properties for a combined price of more than $80 million.
The biotech arm of one of the largest global real estate investors was able to capitalize on soaring demand for Bay Area research and development space with a deal to offload two properties for a combined price of more than $80 million.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
Real Estate
Finance and Insurance